Buy Azopt

Azopt

Azopt: Brinzolamide 1% Ophthalmic Solution - Overview

Azopt contains brinzolamide as its active ingredient. It belongs to the eye-care therapeutic class and is supplied as a 1 % ophthalmic solution in a bottle. In Hong Kong, Azopt is a prescription-only medication regulated by the Department of Health under the Pharmacy and Poisons Ordinance.

How Brinzolamide Works in the Eye

• Carbonic anhydrase inhibition - Brinzolamide blocks the enzyme carbonic anhydrase-II located in the ciliary body of the eye.
• Reduced aqueous humor production - By inhibiting this enzyme, the formation of aqueous humor decreases, leading to lower intra-ocular pressure (IOP).
• Onset and duration - The pressure-lowering effect typically begins within a few hours after instillation and persists for around 12 hours, which is why twice-daily dosing is common.

Conditions Treated with Azopt

• Primary open-angle glaucoma - A chronic condition where drainage of aqueous humor is impaired, causing progressive optic nerve damage.
• Ocular hypertension - Elevated IOP without visible optic nerve damage, a risk factor for glaucoma.

These indications are approved by the Hong Kong Department of Health and align with approvals in other major jurisdictions such as the U.S. FDA and the European EMA.

Patient Suitability and Contraindications

Who Should Use Azopt?

• Adults diagnosed with primary open-angle glaucoma or ocular hypertension.
• Patients who can reliably administer eye drops twice daily.

Absolute Contraindications

• Known hypersensitivity to brinzolamide, sulfonamides, or any component of the eye-drop formulation.
• Severe renal impairment (e.g., creatinine clearance < 15 mL/min) because systemic absorption can be higher.

Relative Contraindications

• Pregnancy and lactation - Safety data are limited; use only if the potential benefit outweighs the risk.
• Severe hepatic disease - May require dosing adjustment or closer monitoring.
• Concurrent sulfonamide therapy - Potential for cross-reactivity, though systemic exposure from eye drops is low.

Special Populations

• Elderly - May have reduced renal function; consider monitoring IOP response and renal parameters.
• Pediatric - Brinzolamide 1 % is not approved for children under 18 years of age in Hong Kong.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Transient blurred vision after instillation - usually resolves within minutes.
• Minor ocular irritation or a feeling of “grittiness.”
• Unusual taste (bitter or metallic) due to nasolacrimal drainage.

Serious Adverse Events

• Significant ocular inflammation - Persistent redness, pain, or vision loss warrants urgent medical review.
• Systemic sulfonamide reactions - Stevens-Johnson syndrome or severe skin rash (extremely rare).

Drug Interactions

• Other intra-ocular pressure-lowering agents (e.g., prostaglandin analogues, beta-blockers) - May have additive IOP-lowering effects; clinicians often combine agents for better control.
• Systemic carbonic anhydrase inhibitors (e.g., acetazolamide) - Concurrent use can increase the risk of systemic side effects such as metabolic acidosis.
• Sulfonamide antibiotics - Potential cross-reactivity; patients with sulfonamide allergy should discuss alternatives with their provider.

Food and Lifestyle Interactions

• No known food-drug interactions.
• Alcohol does not affect brinzolamide’s ocular action, but excessive drinking may impair coordination when applying eye drops.
• Operating heavy machinery is safe; however, transient blurred vision after dosing may briefly affect visual clarity.

Dosing and Administration Guidelines

• Standard adult dose: Instill one drop of Azopt 1 % into each affected eye twice daily, approximately 12 hours apart (e.g., morning and evening).
• Administration tips
• Wash hands before handling the bottle.
• Tilt the head back, pull down the lower eyelid to create a small pocket, and place a single drop without touching the eye or surrounding skin.
• Close the eye gently for about one minute to enhance absorption.
• Missed dose - If a dose is missed and the scheduled time is still several hours away, skip the missed dose and resume the regular schedule; do not double-dose.
• Overdose - Signs may include severe ocular irritation, blurred vision, or systemic sulfonamide toxicity (e.g., nausea, fatigue). Seek immediate medical attention; there is no specific antidote.
• Discontinuation - Abrupt cessation can lead to a rebound increase in IOP. Physicians may advise a gradual taper or transition to an alternative IOP-lowering therapy.

Monitoring and Follow-Up

• Intra-ocular pressure checks - Typically performed 2-4 weeks after initiation, then every 3-6 months, or as directed by the treating ophthalmologist.
• Renal function - Baseline serum creatinine may be obtained, especially in patients with known kidney disease.
• Ocular health - Periodic slit-lamp examinations to assess for inflammation, corneal health, and lens status.

Storage and Handling

• Store the bottle at room temperature (15-30 °C) away from direct sunlight and moisture.
• Keep the bottle tightly closed when not in use.
• Do not freeze the solution.
• Discard any remaining solution after the expiration date printed on the label, even if the bottle appears clear.
• For safety, keep the medication out of reach of children.

Medication-Specific Glossary

Carbonic anhydrase inhibitor

A class of drugs that block the enzyme carbonic anhydrase, reducing fluid production in the eye and kidneys.

Intra-ocular pressure (IOP)

The fluid pressure inside the eye; elevated IOP is a major risk factor for glaucoma.

Ocular hypertension

Elevated IOP without detectable optic nerve damage or visual field loss.

Medical Disclaimer

This article provides educational information about Azopt and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.